Skip to main content

ICN Pharmaceuticals

(ICN)

has completed its acquisition of all outstanding shares of

Ribapharm

Scroll to Continue

TheStreet Recommends

(RNA)

with little room to spare.

ICN reported Wednesday that 69.33% of Ribapharm shares had been tendered in acceptance of ICN's offer of $6.25 a share for the Ribapharm shares that ICN didn't own. ICN needed to secure 66.67% of the shares by Tuesday, according to an agreement worked out between the two companies.

ICN already owned 80% of Ribapharm's shares. Ribapharm's directors had called the cash tender offer "inadequate," but they agreed to let the deal proceed if enough shares were tendered. ICN had offered $5.60 a share in June but raised the amount earlier this month.

Both companies are based in Costa Mesa, Calif. ICN spun off Ribapharm in April 2002 while still holding about 83% of the spin-off's shares. It had planned to distribute the rest of the shares to Ribapharm shareholders within six months after the IPO.